{
    "info": {
        "nct_id": "NCT04316546",
        "official_title": "A Multi-Cohort Phase 2 Dose-Escalation Study of MK-7075 (Miransertib) in Proteus Syndrome",
        "inclusion_criteria": "* INCLUSION CRITERIA:\n\nAll participants in all Cohorts must meet the criteria below:\n\n* Signed informed consent, and when applicable, signed assent\n* Have a molecular diagnosis of Proteus syndrome with documented somatic AKT1 mutation from a CLIA-certified laboratory or international equivalent.\n* Have progressive and measurable disease (e.g., a measurable manifestation of Proteus syndrome with evidence or report of worsening of manifestation(s)/ in the last 12 months)\n* Adequate organ function as indicated by the following laboratory values:\n\nHematological:\n\n* Hemoglobin (Hgb): >=10.0 g/dL\n* Glycated hemoglobin (HbA1c): <=8% (<=64 mmol/mol)\n* Absolute neutrophil count (ANC): >=1.5 x 10^9/L\n* Platelet count >=150 x 10^9/L\n\nHepatic:\n\n1. Total bilirubin <=2 x upper limit of normal (ULN)\n2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=3 x ULN\n\nRenal:\n\n1. Serum creatinine depending on age:\n\n   2-5 years male and female: <=0.50 mg/dL\n\n   6-10 years male and female: <=0.59 mg/dL\n\n   11-15 years male and female: <=1.2 mg/dL\n\n   >15 years male and female: <=1.5 mg/dL\n\n   Metabolic (lipids):\n   * Cholesterol: <=400 mg/dL (<=10.34 mmol/L)\n   * Triglyceride: <=500 mg/dL (<=5.7 mmol/L)\n   * If a female is of child-bearing potential, documentation of a negative pregnancy test is required prior to enrollment. Sexually active participants (male and female) must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse while on study and for up to 90 days after ending treatment\n   * Ability to complete the questionnaires by the participant and/or his/her caregiver\n\n   The following specific criteria will be used to assign participants to Cohorts:\n\n   Cohort 1 (Proteus syndrome with plantar CCTN) specific criteria:\n\n   -Have at least one plantar CCTN that can accurately be measured by standardized photography. The CCTN is defined as a nevus with at least two gyri and three sulci affecting 10% - 70% of the total surface area of the foot.\n\n   -Male or female participants age greater than or equal to 3 and less than or equal to 16 years old and BSA of greater than or equal to 0.33 m^2\n\n   Cohort 2 (Proteus syndrome without plantar CCTN) specific criteria:\n   * Individuals without an evaluable plantar CCTN\n   * No prior exposure to miransertib\n   * Male or female participants age >=3 years old and BSA of >=0.33 m^2\n\n   Cohort 3 (Proteus syndrome previously treated with miransertib) specific criteria:\n\n   -Participants previously treated with miransertib or currently receiving miransertib under Compassionate Use/Expanded Access or an existing trial (i.e., 16-HG-0014)\n\n   -Male or female participants greater than or equal to 3 years old BSA of greater than or equal to 0.33 m^2\n\n   Note: All participants must meet Cohort-related age criteria by/on the date of the first dose, Cycle 1 Day 1\n\n   EXCLUSION CRITERIA:\n\n   An individual who meets any of the following criteria will be excluded from participation in this study:\n\n   - History of Type 1 or Type 2 uncontrolled diabetes mellitus requiring regular medication (other than metformin or other oral hypoglycemic agents) or fasting glucose greater than or equal to 160 mg/dL ( if >12 years old) and greater than or equal to 180 mg/dL (if less than or equal to 12 years old) at the baseline/screening visit\n\n   -History of clinically significant cardiac disorders:\n\n   --Myocardial infarction (MI) or congestive heart failure defined as Class II-IV per the New York Heart Association (NYHA) classification within six months of the first dose of miransertib (MI occurring >6 months of the first dose of miransertib will be permitted)\n\n   --Grade 2 (per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE v 5.0]) or worse conduction defect (e.g., right or left bundle branch block).\n\n   -Major surgery, radiotherapy, chemotherapy, or immunotherapy within four weeks of the first dose of miransertib\n   * Any experimental systemic therapy for the purpose of treating Proteus syndrome (e.g., sirolimus, everolimus, high dose steroids, alpelisib) within two weeks of the first dose of miransertib, except for participants who were previously or are currently treated with miransertib under a Compassionate Use/Expanded Access program or existing protocol\n\n     * Participants who were previously treated with or currently are receiving miransertib will be enrolled on Cohort 3 and treated according to the Schedule of Assessments/Study Visits defined in this protocol\n   * Intolerance of, or severe toxicity attributed to, AKT inhibitors (e.g., miransertib, uprosertib, afuresertib, ipatasertib)\n   * Concurrent severe uncontrolled illness not related to Proteus syndrome\n\n     * Ongoing or active infection\n     * Known human immunodeficiency virus (HIV) infection malabsorption syndrome\n     * Psychiatric illness/substance abuse/social situation that would limit compliance with study requirements\n   * Pregnant or breastfeeding (contraception requirements can be found above and in the informed consent form)\n   * Inability to comply with study evaluations or to follow drug administration guidelines\n   * Concomitant use of a prohibited medication\n   * Regular tobacco use and/or use of cannabidiol/tetrahydrocannabidiol (CBD/THC), and/or vaping products\nHealthy volunteers allowed\nMust have minimum age of 3 Years\nMust have maximum age of 99 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Ongoing or active infection",
            "criterions": [
                {
                    "exact_snippets": "Ongoing or active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cholesterol: <=400 mg/dL (<=10.34 mmol/L)",
            "criterions": [
                {
                    "exact_snippets": "Cholesterol: <=400 mg/dL (<=10.34 mmol/L)",
                    "criterion": "cholesterol",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 400,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10.34,
                                "unit": "mmol/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Hepatic:",
            "criterions": [
                {
                    "exact_snippets": "Hepatic:",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "criterion not specified"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Cohort 1 (Proteus syndrome with plantar CCTN) specific criteria:",
            "criterions": [
                {
                    "exact_snippets": "Proteus syndrome",
                    "criterion": "Proteus syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "plantar CCTN",
                    "criterion": "plantar cerebriform connective tissue nevus (CCTN)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "-Male or female participants greater than or equal to 3 years old BSA of greater than or equal to 0.33 m^2",
            "criterions": [
                {
                    "exact_snippets": "Male or female participants",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "greater than or equal to 3 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum_age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "BSA of greater than or equal to 0.33 m^2",
                    "criterion": "body surface area (BSA)",
                    "requirements": [
                        {
                            "requirement_type": "minimum_value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.33,
                                "unit": "m^2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to comply with study evaluations or to follow drug administration guidelines",
            "criterions": [
                {
                    "exact_snippets": "Inability to comply with study evaluations",
                    "criterion": "compliance with study evaluations",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Inability ... to follow drug administration guidelines",
                    "criterion": "compliance with drug administration guidelines",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6-10 years male and female: <=0.59 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "6-10 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "male and female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "<=0.59 mg/dL",
                    "criterion": "(unspecified laboratory value)",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 0.59,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11-15 years male and female: <=1.2 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "11-15 years male and female: <=1.2 mg/dL",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 11,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 15,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "11-15 years male and female: <=1.2 mg/dL",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "<=1.2 mg/dL",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.2,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "-History of clinically significant cardiac disorders:",
            "criterions": [
                {
                    "exact_snippets": "History of clinically significant cardiac disorders",
                    "criterion": "cardiac disorders",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to complete the questionnaires by the participant and/or his/her caregiver",
            "criterions": [
                {
                    "exact_snippets": "Ability to complete the questionnaires by the participant",
                    "criterion": "questionnaire completion ability (participant)",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Ability to complete the questionnaires by ... his/her caregiver",
                    "criterion": "questionnaire completion ability (caregiver)",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known human immunodeficiency virus (HIV) infection malabsorption syndrome",
            "criterions": [
                {
                    "exact_snippets": "Known human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "-Major surgery, radiotherapy, chemotherapy, or immunotherapy within four weeks of the first dose of miransertib",
            "criterions": [
                {
                    "exact_snippets": "Major surgery ... within four weeks of the first dose of miransertib",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiotherapy ... within four weeks of the first dose of miransertib",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "chemotherapy ... within four weeks of the first dose of miransertib",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "immunotherapy within four weeks of the first dose of miransertib",
                    "criterion": "immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "--Myocardial infarction (MI) or congestive heart failure defined as Class II-IV per the New York Heart Association (NYHA) classification within six months of the first dose of miransertib (MI occurring >6 months of the first dose of miransertib will be permitted)",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction (MI) ... within six months of the first dose of miransertib (MI occurring >6 months of the first dose of miransertib will be permitted)",
                    "criterion": "myocardial infarction (MI)",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_time_relative_to_first_dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure defined as Class II-IV per the New York Heart Association (NYHA) classification within six months of the first dose of miransertib",
                    "criterion": "congestive heart failure (NYHA classification)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA_class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "occurrence_time_relative_to_first_dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 99 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 99 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 99,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "All participants in all Cohorts must meet the criteria below:",
            "criterions": [
                {
                    "exact_snippets": "All participants in all Cohorts must meet the criteria below",
                    "criterion": "eligibility for further criteria",
                    "requirements": [
                        {
                            "requirement_type": "requirement to meet additional criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male or female participants age >=3 years old and BSA of >=0.33 m^2",
            "criterions": [
                {
                    "exact_snippets": "Male or female participants",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "age >=3 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "BSA of >=0.33 m^2",
                    "criterion": "body surface area (BSA)",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.33,
                                "unit": "m^2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have a molecular diagnosis of Proteus syndrome with documented somatic AKT1 mutation from a CLIA-certified laboratory or international equivalent.",
            "criterions": [
                {
                    "exact_snippets": "Have a molecular diagnosis of Proteus syndrome",
                    "criterion": "Proteus syndrome",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": "molecular"
                        }
                    ]
                },
                {
                    "exact_snippets": "documented somatic AKT1 mutation",
                    "criterion": "AKT1 mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation_type",
                            "expected_value": "somatic"
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "from a CLIA-certified laboratory or international equivalent",
                    "criterion": "laboratory certification",
                    "requirements": [
                        {
                            "requirement_type": "certification",
                            "expected_value": [
                                "CLIA-certified laboratory",
                                "international equivalent"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any experimental systemic therapy for the purpose of treating Proteus syndrome (e.g., sirolimus, everolimus, high dose steroids, alpelisib) within two weeks of the first dose of miransertib, except for participants who were previously or are currently treated with miransertib under a Compassionate Use/Expanded Access program or existing protocol",
            "criterions": [
                {
                    "exact_snippets": "Any experimental systemic therapy for the purpose of treating Proteus syndrome (e.g., sirolimus, everolimus, high dose steroids, alpelisib) within two weeks of the first dose of miransertib",
                    "criterion": "experimental systemic therapy for Proteus syndrome",
                    "requirements": [
                        {
                            "requirement_type": "exposure within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for participants who were previously or are currently treated with miransertib under a Compassionate Use/Expanded Access program or existing protocol",
                    "criterion": "prior or current treatment with miransertib under Compassionate Use/Expanded Access program or existing protocol",
                    "requirements": [
                        {
                            "requirement_type": "prior or current treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signed informed consent, and when applicable, signed assent",
            "criterions": [
                {
                    "exact_snippets": "Signed informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "signed assent",
                    "criterion": "assent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concomitant use of a prohibited medication",
            "criterions": [
                {
                    "exact_snippets": "Concomitant use of a prohibited medication",
                    "criterion": "use of prohibited medication",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Individuals without an evaluable plantar CCTN",
            "criterions": [
                {
                    "exact_snippets": "without an evaluable plantar CCTN",
                    "criterion": "plantar CCTN",
                    "requirements": [
                        {
                            "requirement_type": "evaluable",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Triglyceride: <=500 mg/dL (<=5.7 mmol/L)",
            "criterions": [
                {
                    "exact_snippets": "Triglyceride: <=500 mg/dL (<=5.7 mmol/L)",
                    "criterion": "triglyceride level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 500,
                                        "unit": "mg/dL"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5.7,
                                        "unit": "mmol/L"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent severe uncontrolled illness not related to Proteus syndrome",
            "criterions": [
                {
                    "exact_snippets": "Concurrent severe uncontrolled illness not related to Proteus syndrome",
                    "criterion": "severe uncontrolled illness",
                    "requirements": [
                        {
                            "requirement_type": "concurrence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "relation to Proteus syndrome",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "-Male or female participants age greater than or equal to 3 and less than or equal to 16 years old and BSA of greater than or equal to 0.33 m^2",
            "criterions": [
                {
                    "exact_snippets": "Male or female participants",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "age greater than or equal to 3 and less than or equal to 16 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 16,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "BSA of greater than or equal to 0.33 m^2",
                    "criterion": "body surface area (BSA)",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.33,
                                "unit": "m^2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "- History of Type 1 or Type 2 uncontrolled diabetes mellitus requiring regular medication (other than metformin or other oral hypoglycemic agents) or fasting glucose greater than or equal to 160 mg/dL ( if >12 years old) and greater than or equal to 180 mg/dL (if less than or equal to 12 years old) at the baseline/screening visit",
            "criterions": [
                {
                    "exact_snippets": "History of Type 1 or Type 2 uncontrolled diabetes mellitus requiring regular medication (other than metformin or other oral hypoglycemic agents)",
                    "criterion": "uncontrolled diabetes mellitus (Type 1 or Type 2)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "medication requirement",
                            "expected_value": "regular medication (other than metformin or other oral hypoglycemic agents)"
                        }
                    ]
                },
                {
                    "exact_snippets": "fasting glucose greater than or equal to 160 mg/dL ( if >12 years old)",
                    "criterion": "fasting glucose (age >12 years)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 160,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "fasting glucose ... greater than or equal to 180 mg/dL (if less than or equal to 12 years old)",
                    "criterion": "fasting glucose (age â‰¤12 years)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 180,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function as indicated by the following laboratory values:",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Metabolic (lipids):",
            "criterions": [
                {
                    "exact_snippets": "Metabolic (lipids):",
                    "criterion": "lipid metabolism",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "to be specified (lipid metabolism)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin (Hgb): >=10.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin (Hgb): >=10.0 g/dL",
                    "criterion": "hemoglobin (Hgb) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >=150 x 10^9/L",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >=150 x 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 150,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Psychiatric illness/substance abuse/social situation that would limit compliance with study requirements",
            "criterions": [
                {
                    "exact_snippets": "Psychiatric illness ... that would limit compliance with study requirements",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                },
                {
                    "exact_snippets": "substance abuse ... that would limit compliance with study requirements",
                    "criterion": "substance abuse",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                },
                {
                    "exact_snippets": "social situation that would limit compliance with study requirements",
                    "criterion": "social situation",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have progressive and measurable disease (e.g., a measurable manifestation of Proteus syndrome with evidence or report of worsening of manifestation(s)/ in the last 12 months)",
            "criterions": [
                {
                    "exact_snippets": "progressive and measurable disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable manifestation of Proteus syndrome",
                    "criterion": "Proteus syndrome manifestation",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence or report of worsening of manifestation(s)/ in the last 12 months",
                    "criterion": "Proteus syndrome manifestation",
                    "requirements": [
                        {
                            "requirement_type": "worsening",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2-5 years male and female: <=0.50 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "2-5 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "male and female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "<=0.50 mg/dL",
                    "criterion": "(unspecified laboratory value)",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 0.5,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "-Have at least one plantar CCTN that can accurately be measured by standardized photography. The CCTN is defined as a nevus with at least two gyri and three sulci affecting 10% - 70% of the total surface area of the foot.",
            "criterions": [
                {
                    "exact_snippets": "at least one plantar CCTN",
                    "criterion": "plantar CCTN",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "count"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "can accurately be measured by standardized photography",
                    "criterion": "plantar CCTN",
                    "requirements": [
                        {
                            "requirement_type": "measurability by standardized photography",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CCTN is defined as a nevus with at least two gyri and three sulci",
                    "criterion": "CCTN (nevus) structure",
                    "requirements": [
                        {
                            "requirement_type": "number of gyri",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "count"
                            }
                        },
                        {
                            "requirement_type": "number of sulci",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "count"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "affecting 10% - 70% of the total surface area of the foot",
                    "criterion": "CCTN (nevus) surface area involvement",
                    "requirements": [
                        {
                            "requirement_type": "percentage of foot surface area affected",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 10,
                                        "unit": "%"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 70,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No prior exposure to miransertib",
            "criterions": [
                {
                    "exact_snippets": "No prior exposure to miransertib",
                    "criterion": "exposure to miransertib",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Serum creatinine depending on age:",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine depending on age",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": "age-dependent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Cohort 2 (Proteus syndrome without plantar CCTN) specific criteria:",
            "criterions": [
                {
                    "exact_snippets": "Proteus syndrome",
                    "criterion": "Proteus syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without plantar CCTN",
                    "criterion": "plantar CCTN",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Renal:",
            "criterions": [
                {
                    "exact_snippets": "Renal:",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "criterion not specified"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Note: All participants must meet Cohort-related age criteria by/on the date of the first dose, Cycle 1 Day 1",
            "criterions": [
                {
                    "exact_snippets": "All participants must meet Cohort-related age criteria by/on the date of the first dose, Cycle 1 Day 1",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "meets cohort-related criteria",
                            "expected_value": "by/on the date of the first dose, Cycle 1 Day 1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Hematological:",
            "criterions": [
                {
                    "exact_snippets": "Hematological:",
                    "criterion": "hematological status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "criterion not specified; header only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 3 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 3 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "--Grade 2 (per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE v 5.0]) or worse conduction defect (e.g., right or left bundle branch block).",
            "criterions": [
                {
                    "exact_snippets": "Grade 2 (per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE v 5.0]) or worse conduction defect (e.g., right or left bundle branch block)",
                    "criterion": "conduction defect",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NCI CTCAE v5.0 grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or breastfeeding (contraception requirements can be found above and in the informed consent form)",
            "criterions": [
                {
                    "exact_snippets": "Pregnant or breastfeeding",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Pregnant or breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who were previously treated with or currently are receiving miransertib will be enrolled on Cohort 3 and treated according to the Schedule of Assessments/Study Visits defined in this protocol",
            "criterions": [
                {
                    "exact_snippets": "Participants who were previously treated with or currently are receiving miransertib",
                    "criterion": "prior or current miransertib treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": [
                                "previously treated with miransertib",
                                "currently receiving miransertib"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Cohort 3 (Proteus syndrome previously treated with miransertib) specific criteria:",
            "criterions": [
                {
                    "exact_snippets": "Proteus syndrome",
                    "criterion": "Proteus syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previously treated with miransertib",
                    "criterion": "prior miransertib treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC): >=1.5 x 10^9/L",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC): >=1.5 x 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": ">15 years male and female: <=1.5 mg/dL",
            "criterions": [
                {
                    "exact_snippets": ">15 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">",
                                "value": 15,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "male and female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "<=1.5 mg/dL",
                    "criterion": "laboratory value (unspecified)",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If a female is of child-bearing potential, documentation of a negative pregnancy test is required prior to enrollment. Sexually active participants (male and female) must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse while on study and for up to 90 days after ending treatment",
            "criterions": [
                {
                    "exact_snippets": "If a female is of child-bearing potential, documentation of a negative pregnancy test is required prior to enrollment.",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "Sexually active participants (male and female) must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse while on study and for up to 90 days after ending treatment",
                    "criterion": "contraceptive use or sexual activity",
                    "requirements": [
                        {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "double-barrier contraceptive measures",
                                "oral contraception",
                                "avoidance of intercourse"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during study"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 90,
                                        "unit": "days after ending treatment"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Glycated hemoglobin (HbA1c): <=8% (<=64 mmol/mol)",
            "criterions": [
                {
                    "exact_snippets": "Glycated hemoglobin (HbA1c): <=8% (<=64 mmol/mol)",
                    "criterion": "glycated hemoglobin (HbA1c)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 8,
                                        "unit": "%"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 64,
                                        "unit": "mmol/mol"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Regular tobacco use and/or use of cannabidiol/tetrahydrocannabidiol (CBD/THC), and/or vaping products",
            "criterions": [
                {
                    "exact_snippets": "Regular tobacco use",
                    "criterion": "tobacco use",
                    "requirements": [
                        {
                            "requirement_type": "frequency",
                            "expected_value": "regular"
                        }
                    ]
                },
                {
                    "exact_snippets": "use of cannabidiol/tetrahydrocannabidiol (CBD/THC)",
                    "criterion": "cannabidiol/tetrahydrocannabidiol (CBD/THC) use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "vaping products",
                    "criterion": "vaping product use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Total bilirubin <=2 x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin <=2 x upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intolerance of, or severe toxicity attributed to, AKT inhibitors (e.g., miransertib, uprosertib, afuresertib, ipatasertib)",
            "criterions": [
                {
                    "exact_snippets": "Intolerance of ... AKT inhibitors (e.g., miransertib, uprosertib, afuresertib, ipatasertib)",
                    "criterion": "AKT inhibitor intolerance",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe toxicity attributed to ... AKT inhibitors (e.g., miransertib, uprosertib, afuresertib, ipatasertib)",
                    "criterion": "severe toxicity to AKT inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "attribution",
                            "expected_value": "AKT inhibitors"
                        }
                    ]
                }
            ]
        },
        {
            "line": "-Participants previously treated with miransertib or currently receiving miransertib under Compassionate Use/Expanded Access or an existing trial (i.e., 16-HG-0014)",
            "criterions": [
                {
                    "exact_snippets": "Participants previously treated with miransertib",
                    "criterion": "prior miransertib treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "currently receiving miransertib under Compassionate Use/Expanded Access or an existing trial (i.e., 16-HG-0014)",
                    "criterion": "current miransertib treatment",
                    "requirements": [
                        {
                            "requirement_type": "current treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment context",
                            "expected_value": [
                                "Compassionate Use",
                                "Expanded Access",
                                "existing trial (i.e., 16-HG-0014)"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "EXCLUSION CRITERIA:",
            "criterions": []
        },
        {
            "line": "* INCLUSION CRITERIA:",
            "criterions": []
        },
        {
            "line": "An individual who meets any of the following criteria will be excluded from participation in this study:",
            "criterions": []
        },
        {
            "line": "2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=3 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) <=3 x ULN",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) <=3 x ULN",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "The following specific criteria will be used to assign participants to Cohorts:",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}